Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

   By Saabira Chaudhuri 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
05/18 ELI LILLY AND : Findings from Eli Lilly and Company in the Area of Nucleoprotein..
05/18 ELI LILLY AND : Lilly Announces Positive Results for Three Phase 3 Studies of Ga..
05/18 ELI LILLY AND : Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporat..
05/18 ELI LILLY AND : The Faces of Medicine
05/17 ELI LILLY AND : Lilly to Present Results from Pivotal Breast Cancer Study of Abe..
05/17 ELI LILLY AND CO (NYSE : LLY) Jardiance Beats Johnson & Johnson (NYSE:JNJ) Invok..
05/17 ELI LILLY AND : Ensuring Universal Access is a Political Choice
05/16 ELI LILLY AND : Actress Angela Bassett joins For Your SweetHeart™ to urge ..
05/15 ELI LILLY AND : What's up ahead for the pharmaceutical sector in France?
05/12DJELI LILLY AND : Lilly's New Migraine Drug Shows Positive Results
More news
Sector news : Pharmaceuticals - NEC
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/21 WEEK IN REVIEW : Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
05/19 Asco Preview - Breast Cancer And I-O Combos Grab The Early Headlines
05/19 ANAVEX LIFE SCIENCES : 5 Reasons Why I'm Short
05/19 European Ad Comm backs Sanofi's Humalog biosimilar
Financials ($)
Sales 2017 22 090 M
EBIT 2017 5 505 M
Net income 2017 3 246 M
Debt 2017 4 852 M
Yield 2017 2,68%
P/E ratio 2017 29,60
P/E ratio 2018 19,62
EV / Sales 2017 4,11x
EV / Sales 2018 4,02x
Capitalization 85 841 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 89,1 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO5.78%85 841
JOHNSON & JOHNSON10.23%342 117
ROCHE HOLDING LTD.14.79%235 098
NOVARTIS AG6.28%210 347
PFIZER INC.-0.06%193 303
MERCK & CO., INC.8.34%174 449
More Results